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Abstract Cell migration is central to skeletal muscle
repair following damage. Leucine and b-Hydroxy b-
methylbutyric acid (HMB) are supplements consumed
for recovery from muscle damaging exercise in
humans, however, their impact on muscle cell migra-
tion with age is not yet understood. We hypothesised
that replicatively aged (‘‘aged’’; P46–P48) myoblasts
would be less efficient at basal and supplemented
repair versus parental controls (‘‘control’’; P12–P16).
Aged and control myoblasts were scratch-damaged
and migration velocity, directionality and distance
assessed over 48 h in the absence and presence of
leucine (10 mM) or HMB (10 mM) ± PI3K/Akt
(LY294002 10 lM), ERK (PD98059 5 lM) or mTOR
(rapamycin 0.5 lM) inhibition. Opposing our hypoth-
esis, aged cells displayed increased velocities, direc-
tionality and distance migrated (P\ 0.001) versus
control. Leucine and HMB significantly increased
(P\ 0.001) the same parameters in control cells. The
supplements were with smaller, albeit significant
impact on aged cell velocity (P\ 0.001) and in the
presence of HMB only, distance (P = 0.041). Inhi-
bitor studies revealed that, PI3K and ERK activation
were essential for velocity, directionality and migra-
tion distance of aged cells in basal conditions, whereas
mTOR was important for directionality only. While
PI3K activation was critical for all parameters in
control cells (P\ 0.001), inhibition of ERK or mTOR
improved, rather than reduced, control cell migration
distance. Enhanced basal velocity, directionality and
distance in aged cells required ERK and PI3K
activation. By contrast, in control cells, basal migra-
tion was underpinned by PI3K activation, and facil-
itated by leucine or HMB supplementation, to
migration levels seen in aged cells. These data suggest
that replicatively aged myoblasts are not anabolically
resistant per se, but are capable of efficient repair,
underpinned by altered signaling pathways, compared
with unaged control myoblasts.
Keywords Myoblast ! HMB ! Leucine ! PI3K !
ERK ! mTOR ! Damage ! Ageing
Introduction
During the human lifespan, a gradual loss of skeletal
muscle mass and strength occurs, referred to as
sarcopenia. While muscle mass and strength in young
individuals can be preserved through nutritional
supplementation, it is reported that muscle in older
adults displays a level of anabolic resistance (Breen
and Phillips 2011). The capacity of the muscle to
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regenerate following exercise induced muscle damage
is reportedly impaired in ageing rodents and humans
(Brooks and Faulkner 1988; Faulkner et al. 1991). It is
reported that altered satellite cell behaviour may
negatively impact not only on muscle mass and
strength, but also on the muscle regeneration processes
(Welle 2002; Shefer et al. 2006; Day et al. 2010; Bigot
et al. 2015).
Recently, interest has arisen relating to the use of
nutraceuticals to facilitate muscle growth. Data sug-
gest old muscle may be anabolically resistant and
require higher concentrations of protein to elicit a
hypertrophic response versus young muscle (Breen
and Phillips 2011). Leucine, an essential amino acid, is
reportedly a potent anabolic agent (Koopman et al.
2006) and is also consumed following damaging
exercise, with the aim to improve muscle regeneration
(Farup et al. 2014). Recent studies have investigated
the effects of leucine administration on myoblast
fusion (Areta et al. 2014; Dai et al. 2015) and
demonstrated that increasing leucine in a dose respon-
sive manner (5 and 16.5 mM) stimulated the mTOR
signaling pathway and the phosphorylation of
P70S6K, resulting in significantly increased myoblast
fusion. Furthermore, in young recreationally active
males, whey protein, which contains high doses of
leucine (8 g per 100 g), increased muscle satellite cell
number at 48 h post eccentric damage, compared with
control (Farup et al. 2014).
Hydroxy b-methylbutyric acid (HMB), a metabo-
lite of leucine, is increasing in popularity as an
ergogenic aid for muscle recovery and regeneration.
HMB studies in human myoblasts and rodents demon-
strate positive effects on satellite cell proliferation,
differentiation and survival, following MAPK/ERK
and PI3K/Akt activation (Kornasio et al. 2009; Vallejo
et al. 2016). Supplementation of human myoblasts
with HMB (0–85 mM) stimulated cell proliferation
via the MAPK/ERK pathway and induced differenti-
ation via the PI3K/Akt pathway (Kornasio et al. 2009).
Further studies by Vallejo et al. (2016) investigated
the impact of HMB on C2C12 myoblasts (25–125 lM)
and on the contractile force of ageing murine soleus
muscle (514 mg/kg). HMB treatment increased C2C12
myoblast proliferation andmyoblast viability. In mice,
HMB prolonged force generation and reduced the
amount of time for peak muscle contraction following
damage (Vallejo et al. 2016). Together, these studies
indicated that leucine and HMB could impact posi-
tively on muscle differentiation, survival and function.
Adequate skeletal muscle mass and function are
essential in supporting human health and well-being
[reviewed in (Sharples et al. 2015)]. However, the
molecular regulators of skeletal muscle cell migration
are relatively understudied, despite the fact that
skeletal muscle has a remarkable ability to regenerate.
Understanding the signaling pathways that regulate
myoblast migration, direction and velocity is therefore
important in advancing capacity to promote skeletal
muscle regeneration. Evidence exists supporting the
role of the Rho family, in regulating satellite cell
migration (Raftopoulou and Hall 2004). Upstream of
the Rho family is the PI3K/Akt pathway, which we
demonstrated, when inhibited, resulted in impaired
myoblast migration (Dimchev et al. 2013). Further-
more, the MAPK/ERK pathway is also reportedly
involved in efficient myoblast migration, albeit find-
ings are somewhat equivocal (Leloup et al. 2007;
Ranzato et al. 2009; Al-Shanti et al. 2011).
Given a global drive to reduce/refine animal
research, relevant cell models are required to inform
future in vivo studies. To this end, we have developed
a myoblast model, with application to ageing muscle
cell behavior (Sharples et al. 2011). Using a process of
replicative ageing, C2C12 murine skeletal muscle cells
were subjected to 58 population doublings versus
parental control and were reported to display impaired
differentiation both in 2-D and 3-D models (Sharples
et al.2011, 2012; Deane et al. 2013). While these cells
have been extensively characterised with regards to
hypertrophy and atrophy and compare well with
replicatively aged human cells (Bigot et al. 2008),
human and rodent cells isolated from ageing muscle
(Lees et al. 2006; Bigot et al. 2008; Le´ger et al. 2008;
Lees et al. 2009; Pietrangelo et al. 2009) and muscle
biopsy tissue derived from older individuals (Welle
et al. 2003; Le´ger et al. 2008), little research has
focused on their ability to repair damage. Furthermore,
although the potential of nutraceuticals in muscle
preservation is being avidly investigated (Phillips et al.
2009), the question remaining to be challenged is
whether nutraceuticals elicit a beneficial impact on
muscle cell migration and repair and whether this is
compromised with ageing.
Therefore, the goal of this study is to investigate the
impact of leucine and HMB on control and aged
skeletal muscle cell repair. The objectives are: 1. To
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determine the migration capacity of replicatively aged
(but not senescent) C2C12 skeletal muscle cells versus
controls that have not undergone any population
doublings relative to aged cells. 2. To investigate the
impact of the nutritional supplements leucine and
HMB on migration capacity and; 3. To begin to
determine relevant signaling pathways (PI3K, ERK
and mTOR) that may be important for successful
migration and wound closure. We hypothesised that:
(1) replicatively aged (P46–P48; ‘aged’) myoblasts
would be less efficient at damage repair versus unaged
controls (P12–P16, ‘control’); (2) leucine and HMB
would increase the migration potential in control but
not aged cells and; (3) that the PI3K and ERK, but not
mTOR (given its critical role in myoblast fusion)
pathways would be required for effective migration in
both models.
Methods
Cell culture
All cell culture procedures were conducted using a
Kojair Biowizard Silverline class II hood (Kojair,
Vippula, Finland). Commercially available C2C12
mouse skeletal myoblasts were purchased from ATCC
and passages 12–16 (referred to as ‘control’) and
passages 44–48 (replicative aged and referred to as
‘aged’; (130–140 population doublings)) were used in
this study. The cells were incubated in a HERAcell
150i incubator (Thermo Scientific, Cheshire, UK) at:
5% CO2 and 37 "C. Cells were resuscitated from
liquid nitrogen storage and seeded onto gelatinised
T75 flasks (Nunc, Roskilde, Denmark) at 1 9 106
cells/ml in growth medium (GM) that consisted of:
Dulbecco’s Modified Eagle Medium (DMEM), 10%
heat-inactivated fetal bovine serum, 10% heat-inacti-
vated newborn calf serum, 2 mM L-glutamine, and
1% penicillin–streptomycin.
Damage protocol and cell treatments
Once 80% confluency was attained, cells were
trypsinized, counted and seeded at 100,000 cells/ml
on gelatinised six or twelve well plates (Nunc,
Roskilde, Denmark) and grown to 80% confluence.
Cells were washed once with PBS prior to an
established in vitro wound/repair model to assess
migration in myoblasts via applying a damaging
scratch to monolayer cells as previously reported by
our group (Dimchev et al. 2013; Owens et al. 2015).
Cells were washed twice with PBS to remove any
debris, prior to dosing in differentiation medium (DM
containing: DMEM, 2% heat-inactivated horse serum,
2 mM L-glutamine, 1% penicillin–streptomycin), in
the absence or presence of leucine (10 mM) or HMB
(10 mM). Doses were selected following basal dose
response studies (0–10 mM, data not shown). In
addition, signaling pathways, in the absence or
presence of leucine or HMB, were manipulated with:
LY294002 (10 lM), inhibitor of PI3K signalling,
PD98059 (5 lm), inhibitor of ERK signalling or
rapamycin (0.5 lM) inhibitor of mTOR (Dimchev
et al. 2013; Hatfield et al. 2015). For inhibitor studies,
cells were allowed to quiesce for 30 min, in DM, prior
to addition of respective inhibitors for 30 min,
followed by supplements for up to 48 h. All cell
experiments were repeated 3 times in duplicate.
Wound healing assay and migration analysis
For the wound/repair healing assays, immediately
following treatment, cells were incubated in a con-
trolled live imaging environment (Leica DMB 6000;
equipped with PeCon incubation and gas control
system) at 37 and 5% CO2. Microscopic images were
obtained from two points within each wound (using
track and find), every 30 min for 48 h at 910
magnification. For the analysis of cell migration
dynamics, the directionality, accumulated distance
and velocity were determined using TIF image stacks
and Image J software (IBIDI, Munich, Germany). The
manual tracking and chemotaxis plug-ins were
installed which allowed for individual cell trajectory
and migration to be analysed. The chemotaxis tool
analyses the raw data from the manual tracking plug-in
and provides quantitative data on cell directionality
(arbitrary units), velocity (lm/min) and accumulated
distance (lm).
Cell fixation and preparation for flow cytometry
FLOW cytometry was performed to simultaneously
assess multiple phosphoproteins in relevant cell sam-
ples (Schubert et al. 2009, Sharples et al. 2011).
At * 80% confluence, the cells were washed, dam-
aged and quiesced prior to dosing and harvest as
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detailed above. This 30 min quiescence timepoint was
designated as time 0 h. The cells were either fixed at
time 0 h or dosed with 10 mM leucine or HMB for 15,
60 and 120 min post damage. The cells were washed
twice in PBS prior to trypsinisation, neutralisation and
centrifugation at 775 g for 5 min at 4 "C. The
supernatant was removed and the cells were fixed in
2% paraformaldehyde at room temperature for
60 min. The cells were centrifuged as above and re-
suspended in 100% methanol. Cells were stored at
- 20 "C until further analyses by FLOW. The cells
were washed in FLOW buffer (PBS ? 0.5% FBS) and
centrifuged at 500 g for 5 min at 4 "C and re-
suspended in FLOW buffer. The anti-human/mouse
phospho-AKT (S473; APC; 675/25; 0.5 ug), anti-
human/mouse phospho-ERK1/2 (T202/Y204; Alex-
afluor 488; 533/30; 0.03 ug) and anti-human/mouse
phospho-mTOR (S2448; PerCP; 670/LP; 0.125 ug)
antibodies (Thermo Fisher Scientific inc, Waltham,
USA) were added to each sample and incubated at
room temperature in the dark for 60 min. The cells
were washed a further three times, and re-suspended in
200 ll FLOW buffer. The samples were analysed
using flow cytometry on a BD Accuri C6 flow
cytometer with BD CFlow# Software, collecting
2000 events per sample. Fluorophores used in flow
cytometry can emit photons of multiple energies and
wavelengths, compensation of individual fluorescent
antibodies in multiple detectors was performed to
reduce spectral overlap. Forward scatter and side
scatter gating was performed to ensure single popu-
lations of cells. Together these processes should
reduce data skew and improve accuracy.
Statistical analysis
SPSS Predictive Analytics Software (version 23;
IBM) was used for all statistical analyses. Data were
assessed and normal distribution confirmed. For the
comparison of replicative aging (control vs. aged
C2C12 cells) versus supplements (DM alone, leucine,
HMB) a two by three-way ANOVA was used, where
significant main effects and interactions were present,
the Bonferroni post hoc pairwise comparisons test was
used. For within test comparisons, either, independent
t-tests, or one-way analysis of variance (ANOVA) was
used. All data are presented as mean ± SD and
significance as B 0.05.
Results
Improved migration in replicatively aged
versus unaged control C2C12 skeletal muscle cells
Following scratch damage, aged and control cell
migration into the wound site was measured over 48 h
(Fig. 1). In contrast to our hypothesis, under basal
conditions in replicatively aged versus control cells
respectively, there was a 1.27-fold increase in cell
velocity (0.28 ± 0.07 lm/min-1 vs. 0.22 ± 0.07 lm/
min-1; P\ 0.001; Fig. 2a), a 1.27-fold increase in
directionality (0.71 ± 0.12 vs. 0.61 ± 0.17;
P\ 0.001; Fig. 2b) and a 1.29-fold increase in overall
migration distance (802 ± 202 lm vs.
622 ± 188 lm; P\ 0.001; Fig. 2c). This increased
migration in the aged cells was associated with altered
phosphorylation of Akt, ERK, and mTOR (Fig. 3a, b,
c, respectively). In aged cells ERK activation was
significantly increased (P = 0.028) versus control
cells at 15 min and while still elevated at 60 min,
significance was not attained. Akt phosphorylation
was not different between the two cell groups at
15 min. However, while Akt phosphorylation
decreased in the unaged controls to 60 min where it
plateaued to 120 min, it increased over the time course
in the aged cells reaching significance (P = 0.047)
versus control at 120 min. Finally, mTOR phospho-
rylation did not significantly change over the time
course assessed in aged or control cells and no
significant differences were observed between the
two models.
Wishing to determine whether the altered signaling
profiles evident between the cell models may impact
on improved migration in the replicatively aged
model, inhibitor studies were performed. Cell velocity
was 2.8-fold (0.28 ± 0.07 lm/min-1 vs.
0.10 ± 0.04 lm/min-1; P\ 0.001), directionality,
1.5-fold (0.71 ± 0.12 vs. 0.49 ± 0.20; P\ 0.001)
and overall migration distance, 2.4-fold
(802 ± 202 lm vs. 332 ± 123 lm; P\ 0.001)
greater in the absence versus presence of the PI3K
inhibitor, LY294002, respectively (Fig. 4). Similarly,
when aged cells were incubated with the ERK
inhibitor (PD98059), cell velocity was 1.3-fold
(0.28 ± 0.07 lm/min-1 vs. 0.21 ± 0.08 lm/min1;
P = 0.001), directionality, 1.1-fold (0.71 ± 0.12 vs.
0.64 ± 0.17; P\ 0.001) and accumulated distance
1.3-fold (802 ± 202 lm vs. 618 ± 219 lm;
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P\ 0.001) higher under control versus inhibitor
conditions, respectively (Fig. 4). Indeed, in the pres-
ence of PD98059, migration potential of the aged cells
was reduced to that of control cells, the latter under
control conditions. Finally, under aged control versus
mTOR inhibition (rapamycin administration), despite
a small reduction in velocity versus untreated aged
control (Fig. 4), significance was not attained
(0.24 ± 0.07 lm/min-1 vs. 0.28 ± 0.07 lm/min-1).
Compared with untreated aged control cells in the
presence of rapamycin, directionality was signifi-
cantly reduced by 1.15-fold (0.71 ± 0.12 vs.
0.62 ± 0.17; P\ 0.001), however, this was not
sufficient to significantly reduce overall migration
distance (802 ± 202 lm vs. 697 ± 213 lm).
Having determined central roles for PI3K/Akt and
ERK in all parameters of aged cell migration and
mTOR in directionality, equivalent studies were
performed in the control cell model (Fig. 4). Similar
to the aged cells, compared with control, when
incubated with PI3K/Akt inhibitor (LY294002), cell
velocity was 1.6-fold (0.22 ± 0.07 lm/min-1 vs.
0.14 ± 0.06 lm/min-1, P\ 0.001), directionality,
1.6-fold (0.61 ± 0.17 vs. 0.38 ± 0.18, P\ 0.001)
and accumulated migration distance, 1.45-fold
(622 ± 188 lm vs. 437 ± 174 lm; P\ 0.001)
higher under control versus inhibitor conditions,
respectively. By contrast, compared with control, in
the presence of ERK inhibition via PD98059 admin-
istration, cell velocity (0.22 ± 0.07 lm/min-1 vs.
0.21 ± 0.08 lm/min-1) directionality (0.61 ± 0.17
vs. 0.57 ± 0.15) and overall migration distance
(622 ± 188 lm vs. 678 ± 217 lm; P = 0.013), were
not altered (Fig. 4). Therefore, while ERK inhibition
Aged Control
0h
24h
48h
Fig. 1 Images to show the difference between aged and control cells at 0, 24 and 48 h
Biogerontology
123
reduced the migration potential of aged cells to control
capabilities; it was without impact on control cell
migration. Finally, in complete contrast to the aged
cell model, compared with control, when control cells
were incubated with mTOR inhibitor, rapamycin, cell
velocity was 1.4-fold (0.22 ± 0.07 lm/min-1 vs.
0.31 ± 0.06 lm/min-1; P\ 0.001) higher. Direc-
tionality, which was reduced in aged cells, was
unaltered (0.61 ± 0.17 vs. 0.62 ± 0.16), however, in
line with increased velocity in control cells with
rapamycin, overall migration distance was signifi-
cantly increased by 1.4-fold (622 ± 188 lm vs.
884 ± 180 lm; P\ 0.001) versus control. Indeed,
the enhanced migration potential of control cells in the
presence of rapamycin now was equivalent to that of
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Fig. 2 Bar charts illustrating the differences in cell velocity (a),
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and control over 48 h. The data is shown as mean with SD.
Significance is set at P\ 0.05, and the significance between
aged versus control was indicated using *. The experiment
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with SD. Significance is set at P\ 0.05. Significance was
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aged cells (velocity and distance) under control
conditions (Fig. 4).
Under basal conditions, inhibition of PI3K using
LY294002 resulted in a significant reduction in aged
cell migration velocity vs. control cells
(0.10 ± 0.04 lm/min-1 vs. 0.14 ± 0.06 lm/min-1;
P\ 0.001; Fig. 4a), significantly reduced control cell
directionality versus aged (0.38 ± 0.18 vs.
0.49 ± 0.20; P\ 0.001; Fig. 4b) and resulted in an
overall reduction in migration distance of aged vs.
unaged cells (332 ± 123 lm vs. 437 ± 174 lm;
P\ 0.001; Fig. 4c). By contrast, when administration
of ERK inhibitor, PD98059, there were no significant
differences between control and replicatively aged cell
velocity (0.21 ± 0.08 lm/min-1 vs. 0.21 ± 0.08 lm/
min-1; Fig. 4a). However, despite cell directionality
being reduced in control versus aged cells basally
(0.57 ± 0.15 vs. 0.64 ± 0.17; P = 0.001; Fig. 4b),
overall migration distance was significantly lower in
aged versus control cells with ERK inhibition
(618 ± 219 lm vs. 678 ± 217 lm; P\ 0.05;
Fig. 4c). Finally, the impact of rapamycin on cell
velocity was greater in control versus aged cells
(0.31 ± 0.06 lm/min-1 vs. 0.24 ± 0.07 lm/min-1;
P\ 0.001; Fig. 4a) and despite no differences in cell
directionality (Fig. 4b), rapamycin resulted in a sig-
nificantly increased migration distance in control
versus aged cells (884 ± 180 lm vs.
697 ± 213 lm; P\ 0.001; Fig. 4c).
Effect of leucine and HMB supplementation
on rodent C2C12 skeletal muscle cells migration
To determine whether aged cell migration could be
enhanced, treatment with leucine (10 mM) and HMB
(10 mM) were performed. When supplemented with
leucine, there was a small but significant 1.07-fold
increase in aged cell velocity (0.30 ± 0.07 lm/min-1
vs. 0.28 ± 0.07 lm/min-1; P\ 0.001) and a small
but significant 0.97-fold decrease in directionality
(0.67 ± 0.13 vs. control 0.71 ± 0.12; P = 0.001)
versus untreated control. Together, these changes
were not sufficient to impact on overall migration
distance, which was not different from untreated aged
control (Fig. 5). In the presence of HMB, there was a
small but significant 1.15-fold increase in velocity
(0.32 ± 0.07 vs. 0.28 ± 0.07 lm/min-1; P\ 0.001),
no impact on directionality and an overall 1.15-fold
increase in migration distance versus untreated aged
control (921 ± 215 lm vs. 802 ± 202 lm;
P = 0.041).
In contrast, to aged cells, it was hypothesised, that
migration of control cells would be increased when
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Fig. 4 Bar charts illustrating the differences in cell velocity (a),
directionality (b) and accumulated distance (c) in the aged and
control versus LY294002, PD98059 and rapamycin. The data is
shown as mean with SD. Significance is set at P\ 0.05, and the
significance between the inhibitors versus basal aged and
control cells, was indicated using *. The experiment consisted of
3 repeats all in duplicate
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supplemented with leucine or HMB. In the presence of
leucine, cell velocity was significantly increased by
1.4-fold, (0.31 ± 0.09 lm/min-1; vs.
0.22 ± 0.07 lm/min-1; P\ 0.001) versus untreated
control, directionality was unaltered and overall
migration distance increased by 1.4-fold
(883 ± 250 lm vs. 622 ± 188 lm; P\ 0.001).
Indeed, in the presence of leucine, the enhanced
velocity (0.31 ± 0.09 lm/min-1) and overall migra-
tion distance (883 ± 250 lm) of control cells were
now not significantly different from velocity
(0.30 ± 0.07 lm/min-1) and migration distance
(871 ± 202 lm) of aged cells with leucine (Fig. 5).
Similar to leucine, in control cells, HMB supplemen-
tation resulted in a 1.36-fold increase in velocity
(0.30 ± 0.08 lm/min-1 vs. 0.22 ± 0.07 lm/min-1;
P\ 0.001) versus untreated control, no impact on
directionality and a 1.41-fold increase in overall
migration distance (878 ± 219 lm vs.
622 ± 188 lm; P\ 0.001). Despite improved migra-
tion, in the presence of HMB, aged cells still displayed
increased cell velocity (0.32 ± 0.07 lm/min-1 vs.
0.30 ± 0.08 lm/min-1; P\ 0.05), directionality
(0.68 ± 0.14 vs. 0.62 ± 0.17; P\ 0.001) and overall
migration distance (920 ± 215 lm vs.
878 ± 219 lm; P\ 0.05) versus control cells,
respectively (Fig. 5).
Proposed signaling pathways that regulate cell
migration
Having identified the impact of leucine and HMB on
cell migration, the next step was to investigate their
impact on relevant signaling molecules. In line with
the small impact that these supplements had on aged
cell migration, there was little impact on Akt, ERK or
mTOR activation versus untreated aged control.
Indeed, over a 2 h time course, despite small changes
in signaling profiles, no significant differences were
evident between untreated aged control versus leucine
or versus HMB treatment (Fig. 6).
Given the limited impact of leucine or HMB aged
cell migration or on PI3K/Akt, ERK or mTOR
activation versus aged cell controls, the hypothesis
to be challenged next was that these supplements
would not rescue inhibited cell velocity, directionality,
overall migration distance in the presence of
LY294002, PD98059 or rapamycin (Fig. 7a–c),
respectively. Indeed, aged cell velocity was signifi-
cantly blocked by LY294002 in the absence
(0.10 ± 0.04 lm/min-1; P\ 0.001) or presence of
leucine (0.12 ± 0.06 lm/min-1; P\ 0.001) or HMB
(0.12 ± 0.05 lm/min-1; P\ 0.001) versus untreated
aged control (0.30 ± 0.07 lm/min-1). There was no
significant difference between LY294002 alone versus
LY294002 with leucine or with HMB, indicating that
there was no rescue of cell velocity by supplements in
the presence of reduced PI3K/Akt activation (Fig. 7a).
Similar to these data, when treated with LY294002
directionality was significantly reduced in the absence
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Fig. 5 Bar charts illustrating the differences in cell velocity (a),
directionality (b) and accumulated distance (c) in the aged and
control versus leucine and HMB. The data is shown as mean
with SD. Significance is set at P\ 0.05, and the significance
between the supplements versus basal aged and control cells,
was indicated using *. The significance between the aged versus
control was indicated using **. The experiment consisted of 3
repeats all in duplicate
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Fig. 6 Line charts illustrating the differences in the phospho-
rylation of aged Akt (a), ERK (b) and mTOR (c) and control Akt
(d), ERK (e) and mTOR (f) molecules, with cells treated with
leucine and HMB over 120 min. The data is shown as mean with
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in duplicate
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(0.49 ± 0.20; P\ 0.001) or presence of leucine
(0.52 ± 0.19; P\ 0.001) or HMB (0.54 ± 0.22;
P\ 0.001) versus untreated aged control
(0.71 ± 0.12; Fig. 8a). Finally, overall migration
distance in the presence of LY294002 was signifi-
cantly reduced in the absence (332 ± 123 lm;
P\ 0.001) or presence of leucine (388 ± 157 lm;
P\ 0.001) or HMB (399 ± 167 lm; P\ 0.001)
versus untreated aged control (802 ± 202 lm;
Fig. 9a). Interestingly and in contrast to our hypoth-
esis, there was a small but significant increase in
overall migration distance, compared with LY294002,
when co-incubated with either supplement
(P = 0.05).
As with PI3K/Akt inhibition, when aged cells were
treated with PD98059, velocity was significantly
decreased in the absence (0.21 ± 0.08 lm/min-1;
P = 0.001) or presence of leucine (0.24 ± 0.06 lm/
min-1) or HMB (0.23 ± 0.08 lm/min-1), versus
untreated aged control (0.28 ± 0.07 lm/min-1;
Fig. 7b). Similarly, directionality was significantly
reduced in the absence (0.64 ± 0.17; P\ 0.001) or
presence of either leucine (0.67 ± 0.15; P\ 0.001) or
HMB (0.68 ± 0.15; P\ 0.001) versus untreated aged
control (0.71 ± 0.12; Fig. 8b). Overall migration
distance was also significantly blunted when incubated
with PD98059 (618 ± 219 lm; P\ 0.001) versus
untreated aged control (802 ± 202 lm; Fig. 9b).
Interestingly there was a small but significant increase
in overall migration distance, compared with
PD98059 alone, when co-incubated with either sup-
plement (P\ 0.01).
Rapamycin conditions were not significantly dif-
ferent (0.24 ± 0.07 lm/min-1) in cell velocity
(Fig. 7c) versus untreated aged control
(0.28 ± 0.07 lm/min-1) and were not altered by co-
incubation with leucine (0.26 ± 0.06 lm/min-1) or
HMB (0.29 ± 0.07 lm/min-1). Furthermore, rapa-
mycin in absence (0.62 ± 0.17; P\ 0.001) or pres-
ence of leucine (0.64 ± 0.16; P\ 0.001) or HMB
(0.65 ± 0.14; P\ 0.001) significantly reduced the
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cell directionality versus untreated aged control
(0.71 ± 0.12; Fig. 8c). The overall migrated distance
in the presence of rapamycin (697 ± 213 lm;
Fig. 9c) was not significantly different to untreated
aged control (802 ± 202 lm), this was sustained in
the presence of leucine (757 ± 159 lm) or HMB
(849 ± 205 lm). Compared to rapamycin alone, the
co-incubation of leucine did not significantly increase
overall distance, whereas HMB was able to promote
increases in overall distance (P\ 0.001).
Together these data suggest that indeed the ability
of leucine or HMB to rescue aged cell migration in the
presence of inhibited PI3K/Akt or ERK signaling is
compromised. Given the improved basal migration in
control cells supplemented with leucine or HMB and
the roles that PI3K/Akt and ERK appear to play in
control cell migration, the next hypothesis to be tested
was that these supplements may rescue inhibited cell
migration in the presence of PI3K/Akt and ERK but
not mTOR inhibition.
Control cell velocity was significantly reduced with
LY294002 treatment, in the absence
(0.14 ± 0.06 lm/min-1 P\ 0.001) of supplements
versus untreated control (0.22 ± 0.07 lm/min-1). In
the presence of leucine, but not HMB, cell velocity
was increased versus LY294002 (0.19 ± 0.06 lm/
min-1; P\ 0.001), which was not significantly
different from control (Fig. 7a). The directionality of
control cells was significantly blocked when inhibited
with LY294002 (0.38 ± 0.18; P\ 0.001) versus
untreated control (0.61 ± 0.17; Fig. 8a). Co-incuba-
tion with leucine or HMB, respectively, rescued
directionality versus LY294002 alone (0.51 ± 0.16;
P\ 0.001; 0.46 ± 0.21; P = 0.047). The co-incuba-
tion with HMB was rescued back to control, as there
was no significant difference. Despite improvements
in cell velocity and directionality, through co-incuba-
tion with supplements and the small increases in
overall migration distance (Fig. 9a), neither leucine
(495 ± 205 lm) or HMB (476 ± 206 lm) were able
cFig. 8 Bar charts illustrating the differences in cell direction-
ality with the inhibition of LY294002 (a), PD98059 (b), and
rapamycin (c) in the presence or absence of leucine and HMB
over 48 h. The data is shown as mean with SD. Significance is
set at P\ 0.05. Significance was shown as: aged versus control
(^), versus control (*), versus inhibitor (//), leucine vs. HMB (/)
and inhibitor with supplement versus supplement alone (#). The
experiment consisted of 3 repeats all in duplicate
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to significantly increase overall migration distance
versus LY294002 alone (437 ± 174 lm).
Cell velocity did not change when inhibited with
PD98059 (0.21 ± 0.08 lm/min-1) versus control
(0.22 ± 0.07 lm/min-1); it is not therefore surprising
that co-incubation in the presence of either leucine
(0.24 ± 0.06 lm/min-1; P = 0.001) or HMB
(0.23 ± 0.08 lm/min-1; P = 0.032) resulted in
improved cell velocity versus control alone (Fig. 7b).
PD98059 in the absence or presence of supplements
was without impact on directionality (Fig. 8b), how-
ever when compared with control (622 ± 188 lm;
Fig. 9b), migration distance was improved with
PD98059 (678 ± 217 lm; P = 0.013) in the absence
or presence of leucine (756 ± 217 lm; P\ 0.001) or
HMB (742 ± 256 lm; P\ 0.001).
In control cell following rapamycin treatment, there
was an increase in cell velocity (0.31 ± 0.06 lm/
min-1; P\ 0.001) versus control (0.22 ± 0.07 lm/
min-1), which was further enhanced in the presence of
leucine (0.34 ± 0.08 lm/min-1; P\ 0.001) or HMB
(0.35 ± 0.08 lm/min-1; P\ 0.001) vs. untreated
control (Fig. 7c). Indeed, when compared with
rapamycin alone, leucine (P = 0.036) or HMB
(P\ 0.001) co-incubation both also significantly
increased cell velocity versus rapamycin alone. Cell
directionality was unaltered by rapamycin or by
rapamycin plus either supplement (Fig. 8c), however
in the presence of rapamycin, the significant increase
in migration distance (884 ± 180 lm; P\ 0.001)
versus control (622 ± 188 lm; Fig. 9c), was further
enhanced in the presence of leucine (970 ± 232 lm;
P\ 0.001) or HMB (1010 ± 227 lm; P\ 0.001).
Indeed, these increases were significantly higher than
rapamycin alone for both co-incubations with leucine
(P = 0.036) or HMB (P\ 0.001).
Given the unexpected potential of mTOR inhibi-
tion, via rapamycin, to improve not reduce cell
migration, particularly in control cells and wishing
to determine possible compensatory mechanisms,
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Fig. 10 Line charts illustrating the differences in the phospho-
rylation of aged Akt (a), ERK (b) and mTOR (c) and control Akt
(d), ERK (e) and mTOR (f) molecules, with cells treated with
rapamycin over 120 min. The data is shown as mean with SD.
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which may be involved in this adaptation, the cells
were incubated with rapamycin and the phosphoryla-
tion of Akt, ERK and mTOR were analysed. In both
aged and control cells, rapamycin led to a significant
decrease in mTOR phosphorylation. Rapamycin
treated aged cells had suppressed Akt phosphorylation
versus control, there was a significant decrease at
15 min (P = 0.037) versus 0 min, but not at any other
time points (Fig. 10a). There was no difference
between ERK (Fig. 10b) and mTOR (Fig. 10c) in
aged cells until 60 min, where activity decreased in
control, and increased with rapamycin. Similar to Akt,
mTOR phosphorylation was greatly suppressed with
rapamycin treatment versus control over 120 min. In
control cells, Akt phosphorylation was also signifi-
cantly reduced with rapamycin treatment at 15, 60 and
120 min versus 0 min (P = 0.005; P = 0.009;
P = 0.014 respectively; Fig. 10d). The activation of
ERK was reduced and suppressed until 60 min
(Fig. 10e). At 120 min ERK activation spiked, which
is contrary to the treatments. Rapamycin treated cells
significantly reduced mTOR phosphorylation at
15 min (P = 0.026) and 60 min (P = 0.026) versus
0 min (Fig. 10f). At 120 min, the levels increase back
to baseline and at 15 min, there was a significant
difference between control versus rapamycin treat-
ment (P = 0.035).
Discussion
The aim of this study was to determine the capacity of
replicatively aged versus non-replicated control cells
to migrate, the signaling mechanisms underpinning
this capacity and whether leucine and/or HMB could
impact models of skeletal myoblast repair. We
hypothesised that: (1) replicatively aged (P46–P48;
‘‘aged’’) myoblasts would be less efficient at damage
repair versus control (P12–P16; ‘‘control’’); (2)
leucine and HMB would increase the migration
potential in control but not aged cells and; (3) that
the PI3K and ERK but not mTOR pathways would be
required for effective basal migration in both models.
The main outcome of this investigation and in
contrast to hypothesis 1, was that under basal condi-
tions, the aged passaged cells closed the wound more
quickly compared to their control counterparts. This
was evident in the overall velocity, directionality and
accumulated distance of the cells. However, in
accordance with our hypothesis 2, the supplementa-
tion of leucine or HMB enhanced the migration
potential of control cells compared to the aged cells.
Interestingly, the enhanced migration of control cells,
in the presence of supplements, resulted in overall
migration distances equivalent to those obtained in
aged cells in the absence of supplements, suggesting
the control cells were ‘‘catching up’’ with aged cells,
following supplementation. Finally, in accordance
with hypothesis 3, PI3K and ERK were important for
basal migration in both models, but in contrast to
predictions, mTOR inhibition, not activation, enabled
facilitated wound repair in the absence or presence of
supplements and most markedly in control versus aged
cell models.
To date, when studying the impact of age and
nutrition on muscle adaptation, the majority of pub-
lished research has focused on sarcopenia (Church-
ward-Venne et al. 2014), the progressive loss of
muscle mass and strength with age and on anabolic
resistance in aged individuals (Burd et al. 2013).
However, it is also reported that the capability of the
muscle to regenerate in the aged individuals is
impaired, compared with control counterparts (Jang
et al. 2011). In vitro, mechanistic studies to underpin
this latter observation are, however, currently sparse.
Owens et al. (2015) investigated the impact of vitamin
D on muscle regeneration in primary human muscle
cells, and reported average control migration rates
equivalent to those in this model (666 ± 288 vs.
622 ± 188 lm). Our data challenge our hypothesis of
impaired migration with age, with aged cells migrat-
ing more efficiently than control ones, perhaps as a
result of improved PI3K/Akt and ERK signaling. The
improved wound closure is not a result of cellular
replication, with previous studies using mitomycin-C
to block proliferation in unaged and aged myoblasts
reporting migration capabilities which remain intact
(Falcone et al. 1984; Dimchev et al. 2013). Replica-
tively aged C2C12 myoblasts also retain telomeres
(Yaffe and Saxel 1977; Holt et al. 1996; O’connor
et al. 2009) and express decreased levels of IGF-1 and
Akt phosphorylation (Benbassat et al. 1997; Le´ger
et al. 2008), similar to aged primary muscle stem cells.
The absence of a response to leucine and HMB
supplementation in aged cells may arise as a result of
optimised migration under basal conditions—this is
supported via the observation that when control cells
are supplemented with either leucine or HMB,
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migration is significantly improved, but only to levels
seen in untreated aged cells.
To substantiate this theory, in both cell models,
when the PI3K/Akt pathway was inhibited, the cell
velocity, directionality and accumulated distance all
decreased, suggesting that this pathway is integral to
myoblast migration. The basal enhancement in the
aged versus control cells may account for improved
migration under control conditions. Neither leucine
nor HMB were able to rescue reduced migration in the
presence of LY294002, suggesting the fundamental
role of this pathway in effective migration of
myoblasts. Interestingly, while PD98059 reduced
basal velocity and distance migrated in aged cells, it
was without impact in control cells extending our
observations to suggest that PI3K and ERK function
together to facilitate increased migration in aged
versus control cells. Under inhibitor conditions and
unlike PI3K inhibition, co-incubation with leucine or
HMB incurred partial rescue to the aged cell velocity
and migration distance. By contrast, while basal
velocity and overall migration distance were not
negatively impacted by PD98059 in control cells, the
facilitated migration velocity and distance in the
presence of leucine or HMBwas significantly reduced,
compared with either supplement alone. Therefore,
while partial rescue can be incurred via supplemen-
tation in aged cells when ERK is inhibited, the
capacity of control cells to respond to supplements is
reduced in the absence of ERK activation, despite no
impact on basal cell migration potential. These data
suggest both shared and divergent pathways under-
pinning aged versus control myoblast migration.
Dai et al. (2015) recently researched the effects of
leucine on rat satellite cell proliferation and differen-
tiation. The authors reported that leucine promoted
proliferation and differentiation through the mTOR-
MyoD signalling pathway. Research reinforcing these
results demonstrated that leucine starvation led to
inhibition of myoblast differentiation (Averous et al.
2012). Areta et al. (2014) also demonstrated the
benefits on supplementing leucine on C2C12 muscle
cell growth. Research by Kornasio et al. (2009) is the
only study, to the author’s knowledge, to investigate
the effects of HMB on aged myoblast activity. This
study suggested that HMB stimulated myoblast pro-
liferation, differentiation and survival compared to
control, with both the PI3K/Akt and ERK/MAPK
signalling pathways involved in these processes. Cell
migration was not assessed. Further, studies by
Kornasio et al. support the concept that HMB has
beneficial effects on the proliferation and differenti-
ation of myoblasts, through the MAPK/ERK and
PI3K/Akt pathways (Kornasio et al. 2009; Vallejo
et al. 2016). Although migration in the presence of
supplements was not investigated in these reports, data
from Dimchev et al. suggest that the ability of
myoblasts to migrate depends on the PI3K/Akt and
ERK/MAPK pathways (Dimchev et al. 2013).
The data from our study support the hypothesis that
when inhibiting the PI3K/Akt pathwaywith LY294002,
the cell velocity, directionality and accumulated dis-
tance is reduced. Previous studies have supported this
finding (Suzuki et al. 2000; Kawamura et al. 2004; Al-
Shanti et al. 2011; Dimchev et al. 2013). Raftopoulou
and Hall (2004) suggested that the PI3K/Akt pathway is
integral in the development of cellular protrusions.
Moreover, Kawamura et al. (2004) demonstrated that
the PI3K/Akt pathway is essential for cell migration
through lamellipodial formation, which is important in
cell directionality and velocity (Raftopoulou and Hall
2004). It is apparent therefore, that the PI3K/Akt
pathway is integral for myoblast migration, irrespective
of the replicative status of the myoblasts. This may not
be the case for ERK activation, where ERK activity
appears important for improved migration of the aged
cells, but not control, in this study. However, the data
underpinning a role for ERK in myoblast migration are
equivocal. For instance, Leloup et al. (2007) suggested
that the ERK/MAPK pathway was responsible for
stimulating growth factor mediated stimulation of
myoblast migration. Conversely, Ranzato et al. (2009)
suggested that it was primarily Akt and p38 MAPK
signaling proteins that stimulated myoblast migration
not the ERK pathway. Whereas, other research has also
supported the notion that the ERK/MAPK pathway was
involved in cell migration (Al-Shanti et al. 2011;
Dimchev et al. 2013). The differences in studies could
be attributed to the dose of inhibitor used as well as the
myoblast models, alternatively, this apparent contro-
versy warrants further investigation, as it may have
important implications for cellular need, for example,
fusion in the control versus migration in the aged
models.
Intriguingly, and not reported in the Kornasio study
(Kornasio et al. 2009), when rapamycin was added to
the wound model detailed in this manuscript, it was
with no impact on basal migration of aged cells, but
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significantly increased, not decreased, cell velocity
and basal migration of control cells, which were both
further increased with co-incubations of leucine or
HMB. The mTOR pathway is largely regarded to be
integral for muscle protein synthesis (MPS) and is
stimulated by both exercise and protein ingestion, and
is further increased when both are combined (Hawley
et al. 2011). Further research proposes that leucine is
the primary initiator of MPS (Churchward-Venne
et al. 2012). The mTOR target is downstream of the
PI3K and Akt signaling cascades which then stimulate
S6K which leads to MPS (reviewed in: (Sharples et al.
2015). The impact of this pathway on muscular
hypertrophy and muscle wasting is well known
(reviewed in: Sharples et al. 2015), however, the
impact on cell migration has not been studied. These
observations would suggest that mTOR activation is
detrimental to control cell migration, but integral to
myoblast hypertrophy/fusion (Averous et al. 2012;
Areta et al. 2014; Dai et al. 2015), again raising the
concept of differential drivers of cellular behavior
with age. Indeed, the data derived in this study suggest
that the PI3K/Akt pathway is an integral pathway,
shared in control and aged cell migration, that ERK
further enhances aged cell migration, but that mTOR
reduces control cell migration. These changing sig-
naling pathways may underpin the adaptation that
appears to have occurred as a result of replicative
ageing.
Conclusion
Taken together, basally, the aged cells migrate more
quickly than control myoblasts, potentially at the
expense of efficient fusion (Sharples et al. 2011).
However, with the supplementation of leucine and
HMB, the capacity of the control cells to migrate is
increased to that of the aged cells. This implies that 1,
the control cells are more responsive to the supple-
ments or 2, that maximal migration capacity has been
attained in aged cells under basal conditions and
therefore supplements cannot improve their migration
capability. In control myoblasts, it is the PI3K/Akt
pathway that appears central for migration, which is in
line with previous research. However, our data show
that the ERK/MAPK pathway is less important for
control myoblast migration, where the results in the
literature are still equivocal. Activation of both
pathways are required for replicatively aged myoblast
migration. To the author’s knowledge, this is the first
study to investigate the potential role of the mTOR
pathway in myoblast migration. The results are
interesting, showing that this pathway, when acti-
vated, could reduce control myoblast migration,
perhaps to ensure successful protein synthesis and
hypertrophy. Differential activation of the PI3K/Akt,
ERK/MAPK and mTOR pathways appear to underpin
the differences observed in control or supplemented
control and aged myoblast migration. Future research
is required to establish further the mechanisms under-
pinning altered migration, including the roles of
lamellipod/filapod formation and actin polarisation;
cell/matrix interactions should also be determined.
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